Skip to content

Author

Kelly Maynard

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Cost-benefit analysis of a potential hepatitis C vaccine: a modelling study.

In the context of heterogeneous treatment scale-up among countries, a hepatitis C vaccine is likely to have a positive return-on-investment when used to vaccinate populations at highest risk of infection.

Farah Houdroge, Phillip Luong, Jessica Zuk et al. · 0 citations